KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Vertex Pharmaceuticals (VRTX) Operating Income (2016 - 2025)

Vertex Pharmaceuticals has reported Operating Income over the past 17 years, most recently at $1.2 billion for Q4 2025.

  • Quarterly results put Operating Income at $1.2 billion for Q4 2025, up 17.53% from a year ago — trailing twelve months through Dec 2025 was $4.2 billion (up 1891.88% YoY), and the annual figure for FY2025 was $4.2 billion, up 1891.88%.
  • Operating Income for Q4 2025 was $1.2 billion at Vertex Pharmaceuticals, up from $1.2 billion in the prior quarter.
  • Over the last five years, Operating Income for VRTX hit a ceiling of $1.2 billion in Q4 2025 and a floor of -$3.5 billion in Q2 2024.
  • Median Operating Income over the past 5 years was $1.0 billion (2022), compared with a mean of $743.1 million.
  • Biggest five-year swings in Operating Income: surged 3019.0% in 2022 and later plummeted 442.43% in 2024.
  • Vertex Pharmaceuticals' Operating Income stood at $877.7 million in 2021, then grew by 17.75% to $1.0 billion in 2022, then fell by 4.35% to $988.5 million in 2023, then grew by 3.79% to $1.0 billion in 2024, then increased by 17.53% to $1.2 billion in 2025.
  • The last three reported values for Operating Income were $1.2 billion (Q4 2025), $1.2 billion (Q3 2025), and $1.2 billion (Q2 2025) per Business Quant data.